A Long-Term Open-Label Treatment and Extension Study of UX003 rhGUS Enzyme Replacement Therapy in Subjects With MPS 7
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 08 Jun 2018
At a glance
- Drugs Vestronidase alfa (Primary)
- Indications Mucopolysaccharidosis VII
- Focus Adverse reactions
- Sponsors Ultragenyx Pharmaceutical
- 01 Jun 2018 Planned End Date changed from 1 Feb 2019 to 1 Jan 2019.
- 01 Jun 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Jan 2019.
- 18 Apr 2017 Status changed from recruiting to active, no longer recruiting.